Update in New Medications for Primary Care



  1. 1.
    US Food and Drug Administration. Center for Drug Evaluation and Research. Drugs @ FDA. FDA approved drug products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed: September 23, 2008.
  2. 2.
    Department of Health and Human Services. Centers for Disease Control and Prevention. Smoking and tobacco use. Fast facts. Available at: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm Accessed: September 23, 2008.
  3. 3.
    Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax 2008.Google Scholar
  7. 7.
    US Food and Drug Administration CfDEaR. Early communication about an ongoing safety review of varenicline (marketed as Chanitx. Available at: Available at http://www.fda.gov/cder/drug/early_comm/varenicline.htm. Accessed: September 23, 2008.
  8. 8.
    US Food and Drug Administration CfDEaR. Information for healthcare professionals on varenicline (marketed as Chantix). Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/vareniclineHCP.htm. Accessed: September 23, 2008.
  9. 9.
    Cherry D, Woodwell D, Rechtsteiner E. National Ambulatory Medical Care Survey: 2005 summary. Advanced data from vital and health statistics; no.387: National Center for Health Statistics; 2007.Google Scholar
  10. 10.
    Ostchega Y, Yoon S, Hughes J, Louis T. Hypertension awareness, treatment, and control–continued disparities in adults: United States, 2005–2006. NCHS data brief no. 3. Hyattsville, MD: National Center for Health Statistics; 2008.Google Scholar
  11. 11.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–26.PubMedCrossRefGoogle Scholar
  16. 16.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRefGoogle Scholar
  17. 17.
    National Center for Health Statistics. Health, United States, 2007. With chartbook on trends in the health of Americans. Hyattsville, MD.; 2007.Google Scholar
  18. 18.
    Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–68.PubMedCrossRefGoogle Scholar
  21. 21.
    American Diabetes Association. Standards of medical care in diabetes- 2007. Diabetes Care. 2007;30(suppl 1):S4–41.CrossRefGoogle Scholar
  22. 22.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.PubMedCrossRefGoogle Scholar
  24. 24.
    Hoogwerf B. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med. 2006;73:477–84.PubMedCrossRefGoogle Scholar
  25. 25.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.PubMedCrossRefGoogle Scholar
  26. 26.
    Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007;335:87.PubMedCrossRefGoogle Scholar
  27. 27.
    Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412.PubMedCrossRefGoogle Scholar
  28. 28.
    Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.PubMedGoogle Scholar
  29. 29.
    Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;147:633–8.PubMedGoogle Scholar
  31. 31.
    Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290:2301–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–55.PubMedGoogle Scholar
  33. 33.
    Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.PubMedCrossRefGoogle Scholar
  34. 34.
    Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–413.PubMedCrossRefGoogle Scholar
  35. 35.
    Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J. 1999;13:125–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64:1279–83.PubMedCrossRefGoogle Scholar
  37. 37.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.PubMedCrossRefGoogle Scholar
  38. 38.
    Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45.PubMedCrossRefGoogle Scholar
  39. 39.
    Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro Hypertension. 2007;50:447–53. discussion 447–53.CrossRefGoogle Scholar
  40. 40.
    Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con Hypertension. 2007;50:454–8. discussion 454–8.CrossRefGoogle Scholar
  41. 41.
    Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension. 2005;46:1053–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2008

Authors and Affiliations

  1. 1.Division of General Medicine and Primary CareBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Division of General Internal Medicine and Primary CareBrigham and Women’s HospitalBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA

Personalised recommendations